Excelimmune has raised $12 million from a private investor. Proceeds will be used by Excelimmune to develop its infectious disease programs, including Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), and to expand its discovery programs to new disease targets beyond infectious diseases through its antibody screening technology.

"We believe HRPAs will provide a safer and more effective treatment option for nocosomial infectious compared to conventional anti-infective drugs. Beyond infectious diseases, HRPAs have broad potential across multiple therapeutic areas, for which we are pursuing partnerships. We are also expanding our personnel and pipeline to further exploit our technology's potential," said Quinton Zondervan, chief executive officer or Excelimmune.